{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:18:44Z","timestamp":1785147524314,"version":"3.55.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Toxicity or treatment failure related to drug-drug interactions (DDIs) are known to significantly affect morbidity and hospitalization rates. Despite the availability of numerous databases for DDIs identification and management, their information often differs. Oral anticoagulants are deemed at risk of DDIs and a leading cause of adverse drug events, most of which being preventable. Although many databases include DDIs involving anticoagulants, none are specialized in them.<\/jats:p><jats:p><jats:bold>Aim and method:<\/jats:bold> This study aims to compare the DDIs information content of four direct oral anticoagulants and two vitamin K antagonists in three major DDI databases used in Switzerland: Lexi-Interact, Pharmavista, and MediQ. It evaluates the consistency of DDIs information in terms of differences in severity rating systems, mechanism of interaction, extraction and documentation processes and transparency.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> This study revealed 2\u2019496 DDIs for the six anticoagulants, with discrepant risk classifications. Only 13.2% of DDIs were common to all three databases. Overall concordance in risk classification (high, moderate, and low risk) was slight (Fleiss\u2019 kappa = 0.131), while high-risk DDIs demonstrated a fair agreement (Fleiss\u2019 kappa = 0.398). The nature and the mechanism of the DDIs were more consistent across databases. Qualitative assessments highlighted differences in the documentation process and transparency, and similarities for availability of risk classification and references.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> This study highlights the discrepancies between three commonly used DDI databases and the inconsistency in how terminology is standardised and incorporated when classifying these DDIs. It also highlights the need for the creation of specialised tools for anticoagulant-related interactions.<\/jats:p>","DOI":"10.3389\/fphar.2024.1332147","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:25:17Z","timestamp":1712035517000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Drug-drug interactions with oral anticoagulants: information consistency assessment of three commonly used online drug interactions databases in Switzerland"],"prefix":"10.3389","volume":"15","author":[{"given":"Claire","family":"Coumau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Schulthess-Lisibach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Lutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Annick","family":"Le Pogam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Csajka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.18553\/jmcp.2006.12.5.383","article-title":"Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies","volume":"12","author":"Abarca","year":"2006","journal-title":"J. Manag. Care Pharm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1331\/154434504773062582","article-title":"Concordance of severity ratings provided in four drug interaction compendia","volume":"44","author":"Abarca","year":"2004","journal-title":"J. Am. Pharm. Assoc. JAPhA"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/jcpt.12508","article-title":"Clinical decision support systems differ in their ability to identify clinically relevant drug interactions of immunosuppressants in kidney transplant patients","volume":"42","author":"Amkreutz","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.29252\/beat-070401","article-title":"Drug related hospital admissions; A systematic review of the recent literature","volume":"7","author":"Ayalew","year":"2019","journal-title":"Bull. Emerg. Trauma"},{"key":"B6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","article-title":"Hospitalisations and emergency department visits due to drug-drug interactions: a literature review","volume":"16","author":"Becker","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.revmed.2015.10.355","article-title":"Appropriateness of the prescriptions of conventional versus new oral anticoagulants at discharge from a department of internal medicine","volume":"37","author":"Bochatay","year":"2016","journal-title":"La Rev. Med. interne"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11239-013-0929-5","article-title":"Pharmacology of the new target-specific oral anticoagulants","volume":"36","author":"Cabral","year":"2013","journal-title":"J. Thromb. Thrombolysis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"916361","DOI":"10.3389\/fphar.2022.916361","article-title":"Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: a brief, updated report","volume":"13","author":"Canonico","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100222","DOI":"10.1016\/j.lanepe.2021.100222","article-title":"Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding","volume":"10","author":"Chang","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6947-7-7","article-title":"Clinical decision support tools: analysis of online drug information databases","volume":"7","author":"Clauson","year":"2007","journal-title":"Med. Inf. Decis. Mak."},{"key":"B13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: food, herbal medicines and drug interactions","volume":"31","author":"Di Minno","year":"2017","journal-title":"Blood Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2050-6511-13-7","article-title":"Validation of a transparent decision model to rate drug interactions","volume":"13","author":"Far","year":"2012","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40262-020-00879-x","article-title":"Drug-drug interactions with direct oral anticoagulants","volume":"59","author":"Foerster","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00228-011-1081-9","article-title":"Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification","volume":"67","author":"Fr\u00f6lich","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/00005650-200212000-00004","article-title":"Improving recognition of drug interactions: benefits and barriers to using automated drug alerts","volume":"40","author":"Glassman","year":"2002","journal-title":"Med. Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study","volume":"110","author":"Gronich","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10557-021-07279-8","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation using P-gp and\/or CYP450-interacting drugs: a systematic review and meta-analysis","volume":"37","author":"Grymonprez","year":"2023","journal-title":"Cardiovasc Drugs Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/pds.2197","article-title":"Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System)","volume":"20","author":"Guzek","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","article-title":"The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding","volume":"49","author":"Hanigan","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/clpt.2011.150","article-title":"Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software","volume":"90","author":"Haueis","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"946351","DOI":"10.3389\/fphar.2022.946351","article-title":"Screening for severe drug-drug interactions in patients with multiple sclerosis: a comparison of three drug interaction databases","volume":"13","author":"Hecker","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/j.1875-9114.2012.01024.x","article-title":"Recommendations for generating, evaluating, and implementing drug-drug interaction evidence","volume":"32","author":"Hines","year":"2012","journal-title":"Pharmacotherapy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Archives Intern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-020-03015-7","article-title":"Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients","volume":"77","author":"Holm","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1186\/s13054-014-0643-5","article-title":"A systematic review of adult admissions to ICUs related to adverse drug events","volume":"18","author":"Jolivot","year":"2014","journal-title":"Crit. Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00228-015-1943-7","article-title":"Drug interaction databases in medical literature: transparency of ownership, funding, classification algorithms, level of documentation, and staff qualifications. A systematic review","volume":"71","author":"Kongsholm","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1111\/bcp.15341","article-title":"Similarity and consistency assessment of three major online drug-drug interaction resources","volume":"88","author":"Kontsioti","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.thromres.2020.07.054","article-title":"The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants","volume":"195","author":"Lee","year":"2020","journal-title":"Thromb. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.thromres.2020.08.016","article-title":"Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review","volume":"194","author":"Li","year":"2020","journal-title":"Thromb. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1345\/aph.1A333","article-title":"Hospital admissions resulting from preventable adverse drug reactions","volume":"36","author":"McDonnell","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4414\/fms.2001.04125","article-title":"Anticoagulation orale: attitudes pratiques","volume":"17","author":"Niederer","year":"2001","journal-title":"Forum Med. Suisse"},{"key":"B35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11239-015-1314-3","article-title":"Pharmacology of anticoagulants used in the treatment of venous thromboembolism","volume":"41","author":"Nutescu","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00228-017-2225-3","article-title":"Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis","volume":"73","author":"Oscanoa","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1197\/jamia.M2808","article-title":"Tiering drug-drug interaction alerts by severity increases compliance rates","volume":"16","author":"Paterno","year":"2009","journal-title":"J. Am. Med. Inf. Assoc. JAMIA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/ejhpharm-2014-000561","article-title":"Evaluation of eight drug interaction databases commonly used in the German healthcare system","volume":"22","author":"Pauly","year":"2015","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/jamia\/ocv011","article-title":"Recommendations to improve the usability of drug-drug interaction clinical decision support alerts","volume":"22","author":"Payne","year":"2015","journal-title":"J. Am. Med. Inf. Assoc. JAMIA."},{"key":"B40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1067\/mcp.2001.115723","article-title":"Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs","volume":"69","author":"Penning-van Beest","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s11096-010-9445-2","article-title":"Evaluation of three brands of drug interaction software for use in intensive care units","volume":"32","author":"Reis","year":"2010","journal-title":"Pharm. world & Sci. PWS"},{"key":"B42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00228-014-1786-7","article-title":"Drug-drug interaction software in clinical practice: a systematic review","volume":"71","author":"Roblek","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-014-0262-8","article-title":"Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support","volume":"38","author":"Scheife","year":"2015","journal-title":"Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/bcp.13580","article-title":"Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study","volume":"84","author":"Sennesael","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e13766","DOI":"10.7759\/cureus.13766","article-title":"Assessing consistency of drug-drug interaction-related information across various drug information resources","volume":"13","author":"Shariff","year":"2021","journal-title":"Cureus"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1001\/jama.2016.16201","article-title":"US emergency department visits for outpatient adverse drug events, 2013-2014","volume":"316","author":"Shehab","year":"2016","journal-title":"Jama"},{"key":"B47","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1517\/14740338.2011.583916","article-title":"A critical evaluation of clinical decision support for the detection of drug-drug interactions","volume":"10","author":"Smithburger","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1345\/aph.1P377","article-title":"Grading the severity of drug-drug interactions in the intensive care unit: a comparison between clinician assessment and proprietary database severity rankings","volume":"44","author":"Smithburger","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1574886314666191003162104","article-title":"What are the characteristics of patients experiencing adverse drug reactions to oral anticogulants and how can such reactions be prevented?","volume":"15","author":"Spada","year":"2020","journal-title":"Curr. Drug Saf."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"B51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5694\/j.1326-5377.2009.tb02832.x","article-title":"Quality of drug interaction alerts in prescribing and dispensing software","volume":"190","author":"Sweidan","year":"2009","journal-title":"Med. J. Aust."},{"key":"B52","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.amjmed.2021.04.003","article-title":"Drug-drug interactions with direct oral anticoagulants: practical recommendations for clinicians","volume":"134","author":"Terrier","year":"2021","journal-title":"Am. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/s0011-393x(00)80036-3","article-title":"Disagreement among drug compendia on inclusion and ratings of drug-drug interactions","volume":"61","author":"ThomasFulda","year":"2000","journal-title":"Curr. Ther. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","article-title":"Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol","volume":"44","author":"Ufer","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","article-title":"Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions","volume":"132","author":"Vazquez","year":"2018","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e2895","DOI":"10.1097\/MD.0000000000002895","article-title":"Interaction between dietary vitamin K intake and anticoagulation by vitamin K antagonists: is it really true? a systematic review","volume":"95","author":"Violi","year":"2016","journal-title":"Med. Baltim."},{"key":"B57","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2125.2006.02809.x","article-title":"Comparative assessment of four drug interaction compendia","volume":"63","author":"Vitry","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11096-008-9191-x","article-title":"Evaluation of frequently used drug interaction screening programs","volume":"30","author":"Vonbach","year":"2008","journal-title":"Pharm. world & Sci. PWS."},{"key":"B59","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1345\/aph.1M475","article-title":"Black box warning contraindicated comedications: concordance among three major drug interaction screening programs","volume":"44","author":"Wang","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1345\/aph.1L255","article-title":"Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia","volume":"42","author":"Wong","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40264-013-0027-9","article-title":"Comparative performance of two drug interaction screening programmes analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients","volume":"36","author":"Zorina","year":"2013","journal-title":"Drug Saf."},{"key":"B62","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/pds.3279","article-title":"Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients","volume":"21","author":"Zorina","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1332147\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:25:19Z","timestamp":1712035519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1332147\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":62,"alternative-id":["10.3389\/fphar.2024.1332147"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1332147","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"article-number":"1332147"}}